Moderna, Inc. MRNA | NASDAQ
After Hours
Next Earnings: Apr 30, 2025
Company Overview:
6.3 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
MRNA Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for MRNA
Based on past 6.3-year performance, here are MRNA growth metrics:
Share price CAGR of +4.3%
Dividend CAGR of +0%
Using MRNA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| MRNA (DRIP) | MRNA - No DRIP | |
|---|---|---|
| Current Price | $28.35 | $28.35 |
| Start Shares | 352.73 | 352.73 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 352.73 | 352.73 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $41.43 | $41.43 |
| Total Dividends | $0 | $0 |
| Final Value | $14,613 | $14,613 |
NOTE: Above numbers are our estimate based on MRNA's Dividend and Price CAGR over past 6.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Moderna, Inc. (MRNA) had its IPO on 2018-12-07, and is trader on NASDAQ stock exchange.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA website: https://www.modernatx.com
